CD47 and serous adenocarcinoma: Subgroup OS analysis pointed out that patients >60, stages III + IV, serous carcinoma, BMI >30, diabetes, and histological grade G3 combined with the high CD47 expression had a poorer prognosis when weighed against those with the low CD47 expression (p < 0.01, Figures 1(c)–(h)).